Argenx Third-Quarter Profit Rises To $506 Million From $344 Million As VYVGART Sales Climb 54%

Argenx now expects combined R&D and SG&A spending of about $4 billion for 2026, including costs from the Forte Biosciences purchase.

Share
Argenx Third-Quarter Profit Rises To $506 Million From $344 Million As VYVGART Sales Climb 54%

Argenx, the Amsterdam immunology company, reported third-quarter profit of $506 million, versus $344 million a year earlier, all attributable to owners of the parent. The company said in its Thursday results release, furnished to the SEC on Form 6-K, that global VYVGART net sales reached $1.7 billion, up 54% year over year.

What the results show

Product net sales were $1,721 million in the third quarter, up from $1,127 million. The company said VYVGART growth was 13% from the second quarter. For the nine months, product net sales were $4,534 million versus $2,866 million.

Operating profit was $486 million, against $346 million a year earlier. For the nine months it was $1,372 million, up from $686 million, and nine-month profit was $1,344 million versus $759 million.

Basic profit per share was $8.07 versus $5.61 a year earlier. Diluted profit per share was $7.80 versus $5.18.

Selling, general and administrative expenses rose to $598 million from $336 million. They included about $150 million of expenses tied to the acquisition of Forte Biosciences. Research and development expenses were $503 million versus $359 million.

Cash, guidance and the Forte deal

Cash, cash equivalents and current financial assets totaled $3.7 billion at September 30, versus $4.4 billion at December 31, 2025. The company paid about $2.1 billion, net of acquired cash, for Forte.

Combined R&D and SG&A expenses are now expected to be about $4 billion for 2026, including Forte transaction-related costs.

CEO Karen Massey said VYVGART "is the foundation of our business and continues to deliver strong performance across gMG and CIDP." gMG is generalized myasthenia gravis and CIDP is chronic inflammatory demyelinating polyneuropathy.

What to watch

Topline Phase 3 results for empasiprubart in multifocal motor neuropathy are expected in December 2026. The company says its sBLA, a supplemental FDA approval application, for VYVGART Hytrulo in immune-mediated necrotizing myopathy is on track for submission by year-end.

The FDA has accepted a pediatric myasthenia gravis application for priority review, with a target action date in February 2027.

The next scheduled results are full-year 2026 figures on February 25, 2027.

Sources